thalidomide has been researched along with Anhidrotic Ectodermal Dysplasia in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Welge-Lüssen, L | 1 |
2 other studies available for thalidomide and Anhidrotic Ectodermal Dysplasia
| Article | Year |
|---|---|
Editorial: Postscript to thalidomide.
Topics: Abnormalities, Drug-Induced; Adult; Age Factors; Child; Child, Preschool; Ectodermal Dysplasia; Fema | 1975 |
[Thalidomide embryopathy with peculiar eye changes].
Topics: Abnormalities, Drug-Induced; Child; Ectodermal Dysplasia; Eye Abnormalities; Eye Manifestations; Fem | 1971 |